Targeted HER2 antibodies continue to account for over half of treatment revenues; meanwhile, immunotherapy-based therapies represent the fastest-growing segment in HER2 gastric oncology. https://www.einpresswire.com/article/833965726/her2-gastric-cancer-therapy-market-set-for-steady-growth-by-2033-datam-intelligence